Investigational New Drugs

Papers
(The H4-Index of Investigational New Drugs is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation41
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes38
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation35
The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells34
IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC434
Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data31
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer31
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines29
MLN0905, a new inhibitor of Polo-like kinase 1 (PLK1), enhances the efficiency of lenalidomide in promoting the apoptosis of multiple myeloma cell lines29
Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate28
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study26
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines26
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors25
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy24
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma21
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia21
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study20
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors20
A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report20
MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer19
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer19
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer19
0.05660605430603